Education and Training
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TG101348
Eligibility
Inclusion Criteria:
- Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential
thrombocythemia)
- At least 18 years of age.
- ECOG PS 0, 1, or 2.
Exclusion Criteria:
- Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy,
corticosteroids, or growth factor treatment within 14 days prior to initiation of
study drug.
- Major surgery or radiation therapy within 28 days prior to initiation of study drug.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrea Linder
6507254047
Not Recruiting